-+ 0.00%
-+ 0.00%
-+ 0.00%

Truist Securities Maintains Buy on Regeneron Pharmaceuticals, Raises Price Target to $780

Benzinga·10/07/2026 17:07:13
Diffusion vocale
Truist Securities analyst Gregory Renza maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Buy and raises the price target from $772 to $780.